Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Petsinis et al. [7] 2017 RS 2/4 MGb 1/1 Mean: 51.5 100% (2/2)
100% (4/4) 		100% (2/2)
NR 		NR 0% (0/2)
0% (0/4) 		NR
1/7 PSOb 1/0 48 0% (0/1)
85.7% (6/7)
Early loss: 1
Late loss: 0 		100% (1/1)
NR 		NR 0% (0/1)
0% (0/7) 		NR
Cillo et al. [36] 2019 CR 1/5 UC+HT 0/1 0.5 0% (0/1)
0% (0/5)
Early loss: 5
Late loss: 0 		Irr. NR 100% (1/1)
100% (5/5)c 		NR
James et al. [46] 2020 CR 1/2 SA 0/1 48 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		NR NR NR
Patel et al. [57] 1998 CR 1/4 FA+SSc 0/1 Up to prosthetic loading 100% (1/1)
100% (4/4)d 		NR NR NR NR
Maló et al. [75] 2016 RS 3/16 MS NR 60 100% (3/3)
100% (16/16) 		NR Mean: 1.63 0% (0/3)
0% (0/16) 		NR
Overall
Other ADs - CR: 3
RS: 2 		9/38 - Ratio: 1/2 Mean: 47.4 77.8% (7/9)
84.2% (32/38)
Of these: 100% (6/6) early loss 		100% (4/4)
100% (1/1) 		Mean: 1.63 14.3% (1/7)
15.6% (5/32) 		NR
Other ADs
+concomitant ADs 		- CR: 2 2/9 - Ratio: 0/2 Mean: 0.5 50% (1/2)
44.4% (4/9)
Of these: 100% (5/5) early loss 		NR/Irr. NR 100% (1/1)
100% (5/5) 		NR

a = weighted mean or median; b = remission at implant placement; c = submental abscess with extension to submandibular spaces; d = late loss NR.
ADs = autoimmune diseases; CR = case report; FA = fibrosing alveolitis; HT = hypothyroidism; Irr. = irrelevant; M/F = male/female; MG = myasthenia gravis; MS = multiple sclerosis; N = number; NR = not reported; PI = peri-implantitis; PSO = psoriasis; RS = retrospective study; SA = sarcoidosis; SSc = systemic scleroderma; UC = ulcerative colitis.